We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App





Menarini Diagnostics Launches New Molecular Test That Distinguishes Between COVID-19 and Flu in 20 Minutes

By LabMedica International staff writers
Posted on 21 Dec 2020
Print article
Image: VitaPCR platform (Photo courtesy of A. Menarini Diagnostics)
Image: VitaPCR platform (Photo courtesy of A. Menarini Diagnostics)
A. Menarini Diagnostics (Florence, Italy) has introduced a new test that, with a single diagnostic test and a single swab, can identify if the patient is positive for COVID-19 or if they have contracted the Influenza A or B viruses.

The test is carried out on the VitaPCR platform, the Point of Care instrument mainly used for the molecular diagnosis of COVID-19, which has been distributed by Menarini since last April and is already being used in hundreds of European facilities and with over 1,400 units placed. With the use of a new kit containing specific reagents, these same devices will, therefore, be able to detect, in just 20 minutes and with great precision, not only SARS-CoV2 viral RNA, but also influenza A and B. Thanks to the use of PCR (Polymerase Chain Reaction) technology, the instrument meets the highest standards of precision and reliability. In addition to being a valid support for healthcare systems, the use of these tests will allow healthcare authorities to avoid preventive isolation of the patient in cases of influenza and, in COVID cases, to promptly initiate the protocol outlined by governments.
Platinum Supplier
ADAMTS13 Activity Assay
HemosIL ADAMTS13 Activity Assay
New
Immunoassay Reader
ichroma II
Visit expo >

The new kit, CE marked is already available and distributed by Menarini in Italy, Austria, Belgium, Germany, Greece, Luxembourg, the Netherlands, Portugal, Spain and the United Kingdom.

"In the coming months, we will see an increase in people with flu-like symptoms that could be attributed to either a SARS-CoV-2 infection or influenza A and B,", said Fabio Piazzalunga, General Manager of Menarini Diagnostics, "This test is of fundamental importance for immediate diagnosis and getting patients the most appropriate treatment promptly."

Related Links:
A. Menarini Diagnostics


Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.